Loading the section
The price of ImmunityBio, Inc. (IBRX) on October 9, 2026 is 10.51 USD, +6.05% on the day. Over 52 weeks the stock traded between 1.95 USD and 12.43 USD; the price now sits 82% of the way up that range. Over the past year the price changed by +315.42%. Market capitalization is 11.01 billion USD, rank 10 among 128 stocks of the same industry with a known capitalization.
Closing prices for 09 October 2026
Next earnings report: 03 November 2026 · Earnings calendar
ImmunityBio, Inc. trades on Nasdaq under the ticker IBRX. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks IBRX has traded between 1.95 $ and 12.43 $. As of 09 October 2026 the price stood 81.68 % of the way from the 52-week low to the high.
Over one year IBRX shares rose 315.42 %; over six months they rose 44.37 %. Volatility over 90 days is 64.66 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 78.1, above the sector median of 4.0. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 9.95 | 10.80 | 9.87 | 10.51 | 19M |
| 08 October 2026 | 9.63 | 10.05 | 9.43 | 9.91 | 10M |
| 07 October 2026 | 9.50 | 9.93 | 9.33 | 9.75 | 12M |
| 06 October 2026 | 10.33 | 10.36 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
ImmunityBio, Inc. (IBRX) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 141.0m $, net income was -854.5m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121, US
ImmunityBio, Inc. reported revenue of 141M $ and a net loss of 855M $ over the last four quarters. Net margin is −606.14 %. Revenue changed by +351.53 % year over year. Earnings per share are −0.85 $. Market capitalisation is 11.0B $.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 110.42 | +0.53 % | 253M |
| BIIBBiogen Inc. | 225.71 | +3.33 % | 227M |
| KODKodiak Sciences Inc | 99.87 | +5.95 % | 219M |
| 9.61 |
| 9.69 |
| 17M |
| 05 October 2026 | 10.76 | 10.81 | 10.13 | 10.38 | 17M |
| 02 October 2026 | 9.39 | 10.55 | 9.39 | 10.29 | 31M |
| 01 October 2026 | 9.28 | 9.40 | 9.07 | 9.28 | 12M |
| 30 September 2026 | 8.92 | 10.09 | 8.90 | 9.44 | 27M |
| 29 September 2026 | 8.52 | 8.88 | 8.52 | 8.83 | 8M |
| 28 September 2026 | 8.39 | 8.98 | 8.26 | 8.52 | 10M |
| 25 September 2026 | 8.76 | 8.84 | 8.41 | 8.44 | 6M |
| 24 September 2026 | 8.50 | 8.68 | 8.31 | 8.64 | 9M |
| 23 September 2026 | 9.26 | 9.29 | 8.60 | 8.63 | 14M |
| 22 September 2026 | 8.45 | 9.48 | 8.37 | 9.29 | 21M |
| 21 September 2026 | 8.72 | 8.87 | 8.26 | 8.45 | 12M |
| 18 September 2026 | 8.46 | 8.53 | 8.20 | 8.48 | 18M |
| 17 September 2026 | 8.14 | 8.80 | 8.12 | 8.46 | 19M |
| 16 September 2026 | 8.14 | 8.30 | 7.76 | 7.91 | 9M |
| 15 September 2026 | 8.32 | 8.34 | 7.85 | 8.14 | 9M |
| 14 September 2026 | 7.89 | 8.40 | 7.87 | 8.37 | 9M |